Kailera Therapeutics (NASDAQ:KLRA) Hits New 12-Month Low - Here's Why

Key Points

• Kailera Therapeutics fell to a new 52-week low of $11.10, well below its 50-day moving average of $16.35, giving the company a market capitalization of approximately $1.47 billion.
• The company reported a quarterly loss of $1.09 per share, missing the consensus estimate of $0.74, while analysts expect a full-year loss of $3.89 per share.
• Analyst sentiment remains mixed but leans positive, with a consensus “Moderate Buy” rating and a $42.75 price target; however, Weiss Ratings initiated coverage with a “sell” rating. Several major institutions, including Wellington Management and Frazier Life Sciences, recently established positions.

Kailera Therapeutics, Inc. (NASDAQ:KLRA - Get Free Report) reached a new 52-week low during trading on Monday. The company traded as low as $11.10 and last traded at $11.23, with a volume of 36610 shares. The stock had previously closed at $11.22.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings started coverage on shares of Kailera Therapeutics in a report on Friday, August 14th. They set a "sell (d)" rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $42.75.

Kailera Therapeutics Stock Performance

The stock has a market capitalization of $1.47 billion and a PE ratio of -0.00. The company's 50-day simple moving average is $16.35.

Kailera Therapeutics (NASDAQ:KLRA - Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.35). On average, research analysts anticipate that Kailera Therapeutics, Inc. will post -3.89 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Tidal Investments LLC purchased a new stake in shares of Kailera Therapeutics in the second quarter worth about $309,000. Squarepoint Ops LLC bought a new stake in Kailera Therapeutics during the second quarter valued at $993,000. State Street Corp purchased a new position in Kailera Therapeutics during the second quarter worth about $19,126,000. Frazier Life Sciences Management L.P. bought a new position in Kailera Therapeutics in the 2nd quarter worth about $24,233,000. Finally, Wellington Management Group LLP bought a new position in Kailera Therapeutics in the 2nd quarter worth about $64,308,000.

Kailera Therapeutics Company Profile

Kailera Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for obesity and related metabolic diseases. The company's programs are designed to address the substantial medical needs associated with excess weight and metabolic disorders.

Kailera's lead product candidate is KAIL-001, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist intended for the treatment of obesity and potentially related conditions. The company is advancing its pipeline through clinical development and regulatory activities, although its products remain investigational and are not yet approved for commercial use.

The company's operations are centered on the development of therapies for global markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.